Sparsentan. Dual angiotensin II AT1 receptor blocker and endothelin ETA receptor antagonist, Treatment of focal segmental glomerulosclerosis, Treatment of IgA nephropathy

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11110%2F20%3A10410629" target="_blank" >RIV/00216208:11110/20:10410629 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00064165:_____/20:10410629

Výsledek na webu

<a href="https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=VBXPncHaI-" target="_blank" >https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=VBXPncHaI-</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1358/dof.2020.45.2.3058863" target="_blank" >10.1358/dof.2020.45.2.3058863</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Sparsentan. Dual angiotensin II AT1 receptor blocker and endothelin ETA receptor antagonist, Treatment of focal segmental glomerulosclerosis, Treatment of IgA nephropathy

Popis výsledku v původním jazyce

Treatment of glomerular diseases remains challenging. There are limited therapeutic options currently available for focal segmental glomerulosclerosis (FSGS) and immunoglobulin A nephropathy (IgAN) and they are generally ineffective in a substantial proportion of patients who progress to end-stage kidney disease during long-term follow-up. Standard management involving renin-angiotensin-aldosterone system (RAAS) inhibitors, corticosteroids and various immunosuppressive therapies does not always achieve sustained, complete or partial remission for most patients while causing serious or intolerable adverse effects. There is a substantial unmet need for new treatments to improve outcomes. Sparsentan, a first-in-class, orally active compound combining angiotensin II type 1 (AT1) receptor blockade with endothelin ETA receptor antagonism, offers an innovative dual mechanism of action approach to the treatment of these diseases with a potentially greater nephroprotective effect, compared to RAAS or endothelin inhibition alone. We summarize the molecular and pharmacological features of sparsentan and discuss ongoing clinical trials in FSGS and IgAN. These trials were designed to examine the long-term antiproteinuric effect, nephroprotective potential and safety profile of sparsentan. We also highlight new efforts to evaluate sparsentan in the treatment of Alport syndrome. This review aims to elucidate the potential role of this novel agent in the management of glomerular diseases.

Název v anglickém jazyce

Sparsentan. Dual angiotensin II AT1 receptor blocker and endothelin ETA receptor antagonist, Treatment of focal segmental glomerulosclerosis, Treatment of IgA nephropathy

Popis výsledku anglicky

Treatment of glomerular diseases remains challenging. There are limited therapeutic options currently available for focal segmental glomerulosclerosis (FSGS) and immunoglobulin A nephropathy (IgAN) and they are generally ineffective in a substantial proportion of patients who progress to end-stage kidney disease during long-term follow-up. Standard management involving renin-angiotensin-aldosterone system (RAAS) inhibitors, corticosteroids and various immunosuppressive therapies does not always achieve sustained, complete or partial remission for most patients while causing serious or intolerable adverse effects. There is a substantial unmet need for new treatments to improve outcomes. Sparsentan, a first-in-class, orally active compound combining angiotensin II type 1 (AT1) receptor blockade with endothelin ETA receptor antagonism, offers an innovative dual mechanism of action approach to the treatment of these diseases with a potentially greater nephroprotective effect, compared to RAAS or endothelin inhibition alone. We summarize the molecular and pharmacological features of sparsentan and discuss ongoing clinical trials in FSGS and IgAN. These trials were designed to examine the long-term antiproteinuric effect, nephroprotective potential and safety profile of sparsentan. We also highlight new efforts to evaluate sparsentan in the treatment of Alport syndrome. This review aims to elucidate the potential role of this novel agent in the management of glomerular diseases.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30217 - Urology and nephrology

Projekt

—

Návaznosti

V - Vyzkumna aktivita podporovana z jinych verejnych zdroju

Rok uplatnění

2020

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Drugs of the Future

ISSN

0377-8282

e-ISSN

—

Svazek periodika

45

Číslo periodika v rámci svazku

2

Stát vydavatele periodika

ES - Španělské království

Počet stran výsledku

20

Strana od-do

79-98

Kód UT WoS článku

000518209600001

EID výsledku v databázi Scopus

2-s2.0-85085623463